|
|
|
|
|
|
|
Alkermes plc (ALKS)
|
|
41.19 -0.45 (-1.08%)
|
10-15 10:58
|
|
Open:
|
41.48
|
Pre. Close:
|
41.64
|
|
High:
|
41.8
|
Low:
|
41.01
|
|
Volume:
|
161,306
|
Market Cap:
|
6397M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
43.321 - 43.608
|
43.608 - 43.867
|
|
Low:
|
40.544 - 40.903
|
40.903 - 41.228
|
|
Close:
|
41.09 - 41.651
|
41.651 - 42.158
|
|
|
|
Technical analysis (as of: 2018-10-15 10:44:31 AM)
|
|
Overall:
|
|
|
Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.
|
|
Target:
|
Six months: 49.65 One year: 52.75
|
|
Support:
|
Support1: 38.23 Support2: 31.81
|
|
Resistance:
|
Resistance1:
42.51 Resistance2: 45.16
|
|
Pivot:
|
42.89 
|
|
Moving Averages:
|
MA(5): 42.08 MA(20): 42.34 
MA(100): 44.21 MA(250): 49.16
|
|
MACD:
|
MACD(12,26):
-0.09 Signal(12,26,9): 0.01
|
|
%K %D:
|
%K(14,3): 10.16 %D(3): 26.09
|
|
RSI:
|
RSI(14): 42.72
|
|
52-Week:
|
High: 71.22
Low: 38.23 Change(%): -19.5
|
|
Average Vol(K):
|
3-Month: 57293
10-Days 53334
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.ALKS has closed above bottom band by 11.0%. Bollinger Bands are 38.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-09-10T07:46:50-04:00
Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors
2018-09-10T07:00:00-04:00
Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
